Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CB | P42338 | 2/20 | 0.47 |
| ▸ | MOK | Q9UQ07 | 4/20 | 0.45 |
| ▸ | RAF1 | P04049 | 9/20 | 0.43 |
| ▸ | BRAF | P15056 | 9/20 | 0.43 |
| ▸ | AKT1 | P31749 | 1/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.40 |
| ▸ | ATR | Q13535 | 1/20 | 0.40 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.40 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.40 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.40 |
| ▸ | CSF1R | P07333 | 1/20 | 0.40 |
| ▸ | PRKDC | P78527 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4103054 | 0.86 | PIK3CB (0.54) | PIK3CBMOKRAF1BRAFPIK3CA | |
| SCHEMBL3593673 | 0.84 | PIK3CB (0.49) | PIK3CBPIK3CACHEK1ATRPDCD1 | |
| SCHEMBL4535605 | 0.84 | PIK3CB (0.53) | PIK3CBPIK3CACHEK1ATRPDCD1 | |
| SCHEMBL4523237 | 0.82 | PIK3CD (0.45) | PIK3CBMOKPIK3CACHEK1ATR | |
| SCHEMBL4264279 | 0.82 | PIK3CB (0.43) | PIK3CBMOKPIK3CAMTOR | |
| SCHEMBL4730672 | 0.81 | PIK3CB (0.51) | PIK3CBAKT1PIK3CAMTOR | |
| SCHEMBL4844051 | 0.81 | PIK3CB (0.55) | PIK3CBMOKPIK3CAMTOR | |
| SCHEMBL4535548 | 0.79 | PIK3CB (0.48) | PIK3CBPIK3CAMTORCHEK1ATR | |
| SCHEMBL4535561 | 0.79 | PIK3CB (0.52) | PIK3CBPIK3CAMTOR | |
| SCHEMBL3987588 | 0.79 | PIK3CB (0.60) | PIK3CBPIK3CAMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325954-A1 | 2-BENZIMIDAZOLYL-6-MORPHOLINO-4-PHENYLPYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325954-A1 | 2-BENZIMIDAZOLYL-6-MORPHOLINO-4-PHENYLPYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | PIK3CA, MTOR, PIK3CD | PIK3CB 4/4885MOK 875/4885RAF1 219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.